Last: 0.04
Change: 0.00
Vol: 0


Technology Overview

Indications to Treat Cutaneous T cell lymphoma


Cutaneous T-cell lymphoma (CTCL) is rare and difficult to recognize malignant tumor of the lymphatic system. The disease is caused by an uncontrolled increase in T lymphocytes located in the lymphatic system of the skin and often mistaken with psoriasis or eczema.

Factors regulating CTCL pathogenesis are still largely unknown, but STAT3 protein, a messenger and transcription factor responsible for CTCL cell proliferation and survival, has been identified as the primary target. STAT3 is the molecular stimulus that triggers CTCL tumor development and tumor-induced immune tolerance.

By targeting the signaling pathway consisting of many factors mediated by p-STAT3, survival, the response rate can be improved and the time to relapse/progression in CTCL patients can be significantly extended.

WP1220 is the first pSTAT3-targeted drug used in monotherapy for patients with CTCL and giving the opportunity to be used in other skin cancers and diseases associated with STAT3.

Clinic Development

WP1220 is already clinical trials in Poland.

Initial Indication

Cutaneous T-cell lymphoma

Partners, Affiliations & License

MD Anderson, leading cancer research center in the world

Moleculin Biotech, Inc. – co-development partner

Market Opportunity

The expected market size is in excess of $1 billion.

Subscribe to our Newsletter